Confirmed Control Closed Transaction verified BiotechMuscular DystrophyPharmaTherapeutics

Edgewise Therapeutics' Muscular Dystrophy Business acquired by Servier

Servier acquired Edgewise Therapeutics' Muscular Dystrophy Business, a therapeutics brand. Financial terms were not publicly disclosed. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.

Transaction summary

Target
Edgewise Therapeutics' Muscular Dystrophy Business
Acquirer
Servier
Seller
Edgewise Therapeutics
Announced
-
Geography
-
Tags
BiotechMuscular DystrophyPharmaTherapeutics
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-07-27
Latest update
2026-08-03

Value and multiples

Price / value

Undisclosed

Transaction value

Basis: FundComb estimate

EV / revenue

-

Period not stated

Basis: FundComb estimate

EV / EBITDA

-

EBITDA basis not stated

Basis: FundComb estimate

Basis

  • Financial terms were not disclosed in the public sources reviewed.

Source summary

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - PR Newswire

Confirmed

A PR Newswire release states that Servier completed its acquisition of Edgewise Therapeutics' muscular dystrophy business.

Open source

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business - PR Newswire

Confirmed

A PR Newswire release states that Servier completed its acquisition of Edgewise Therapeutics' muscular dystrophy business.

Open source